Marshall Wace
VRCA icon

Marshall Wace’s Verrica Pharmaceuticals VRCA Stock Holding History

Marshall Wace’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-140,497
Closed -$743K – 3796
2026
Q1 		$743K Buy
140,497
+55,324
+65% +$354K ﹤0.01% 2277
2025
Q4 		$708K Buy
+85,173
New +$472K ﹤0.01% 2096
2025
Q3 		– Sell
-12,395
Closed -$65.7K – 3454
2025
Q2 		$65.7K Buy
+12,395
New +$66.7K ﹤0.01% 2576
2023
Q3 		– Sell
-5,393
Closed -$311K – 2738
2023
Q2 		$311K Buy
5,393
+4,052
+302% +$246K ﹤0.01% 2130
2023
Q1 		$87.2K Buy
+1,341
New +$81.1K ﹤0.01% 2510
2021
Q3 		– Sell
-3,143
Closed -$355K – 3467
2021
Q2 		$355K Buy
+3,143
New +$381K ﹤0.01% 2271

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace's VRCA Position: Q2 2026 in Review

Marshall Wace sold out of Verrica Pharmaceuticals (VRCA) in Q2 2026, closing a stake of 140,497 shares — an estimated $743K sold.

Marshall Wace first reported a position in VRCA in Q2 2021 and held it in 6 quarters. The position peaked at $743K in Q1 2026. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • Marshall Wace reported no remaining Verrica Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 140,497 Verrica Pharmaceuticals shares in Q2 2026, an estimated $743K.
  • Marshall Wace first reported a position in Verrica Pharmaceuticals in Q2 2021 and held it in 6 quarters.
  • Marshall Wace's Verrica Pharmaceuticals position peaked at $743K in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.